Next Article in Journal
Thymoma-Related Paraneoplastic Syndrome Mimicking Reactive Arthritis
Previous Article in Journal
End-of-Life Decision-Making in Intensive Care Ten Years after a Law on Advance Directives in Germany
 
 
Article

Aspirin Is Related to Worse Clinical Outcomes of COVID-19

1
Department of General Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13488, Korea
2
Department of Orthopedic Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13488, Korea
3
inCerebro Drug Discovery Institute, Seoul Technopark, Seoul 01811, Korea
4
Department of Orthopedic Surgery, Ilsan Paik Hospital, Inje University, Goyang 10380, Korea
5
Department of Orthopedic Surgery, Bucheon Hospital, Soonchunhyang University, Bucheon 14584, Korea
*
Author to whom correspondence should be addressed.
Contributed equally to co-first authors.
Academic Editor: Pierpaolo Di Micco
Medicina 2021, 57(9), 931; https://doi.org/10.3390/medicina57090931
Received: 20 July 2021 / Revised: 1 September 2021 / Accepted: 2 September 2021 / Published: 4 September 2021
Backgroundand Objectives: Aspirin is used globally to reduce pain and inflammation; however, its effect in patients with coronavirus disease (COVID-19) is not fully investigated and remains controversial. We evaluated the association between aspirin and COVID-19 outcomes using nationwide data from the Korean National Health Insurance System. Materials and Methods: This was a retrospective observational cohort study that included 22,660 eligible patients who underwent COVID-19 testing in South Korea between 1 January–31 July 2020. We identified all aspirin users prescribed aspirin within two weeks before or after the index date. The primary outcome was positivity for the COVID-19 test, and secondary outcomes included conventional oxygen therapy, intensive care unit, mechanical ventilation, or death. We applied the propensity score matching method to reduce the possible bias originating from the differences in patients’ baseline characteristics. Results: Of those eligible, 662 patients were prescribed aspirin. Among them, 136 patients were on aspirin within two weeks before diagnosis and 526 patients were on aspirin after diagnosis. The COVID-19 test positivity rate was not significantly different according to aspirin use. Aspirin use before COVID-19 was related to an increased death rate and aspirin use after COVID-19 was related to a higher risk of the conventional oxygen therapy. Conclusion: Aspirin use was associated with adverse effects in COVID-19 patients. Further studies for mechanisms are needed. View Full-Text
Keywords: COVID-19; aspirin; outcome COVID-19; aspirin; outcome
Show Figures

Figure 1

MDPI and ACS Style

Kim, I.; Yoon, S.; Kim, M.; Lee, H.; Park, S.; Kim, W.; Lee, S. Aspirin Is Related to Worse Clinical Outcomes of COVID-19. Medicina 2021, 57, 931. https://doi.org/10.3390/medicina57090931

AMA Style

Kim I, Yoon S, Kim M, Lee H, Park S, Kim W, Lee S. Aspirin Is Related to Worse Clinical Outcomes of COVID-19. Medicina. 2021; 57(9):931. https://doi.org/10.3390/medicina57090931

Chicago/Turabian Style

Kim, Isaac, Siyeong Yoon, Minsup Kim, Hyunil Lee, Sinhyung Park, Wonsang Kim, and Soonchul Lee. 2021. "Aspirin Is Related to Worse Clinical Outcomes of COVID-19" Medicina 57, no. 9: 931. https://doi.org/10.3390/medicina57090931

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop